Quick Answer
Candel Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $125.0 thousand for the year ending 2022.
- Candel Therapeutics, Inc. showed an increase of +0.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from Candel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 28, 2024.
- XBRL data for this metric is available from 2020 to 2022 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $31.0 thousand | Q3 2020: $31.0 thousand | Q1 2021: $31.0 thousand | Q2 2021: $31.0 thousand | Q3 2021: $31.0 thousand | Q1 2022: $31.0 thousand | Q2 2022: $31.0 thousand | Q3 2022: $31.0 thousand.
- Over the full 3 years of available data (2020 to 2022), Candel Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 0.0%.
- Historical annual values: Fiscal year 2022: $125.0 thousand | Fiscal year 2021: $125.0 thousand | Fiscal year 2020: $125.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: